AL Amyloidosis clinical trials at UCLA

1 in progress, 0 open to eligible people

NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis
Sorry, in progress, not accepting new patients
Open-label Phase 1b Dose Escalation/Dose Expansion study exploring the safety and efficacy of NXC-201 in patients with relapsed or refractory light chain amyloidosis (AL).
Los Angeles, California and other locations

Last updated: July 12, 2026